Table 1

Summary of the most significant results in univariate analysis of the association of ocular and systemic factors with the number of anti-VEGF injections required over 2 years of Observe-and-Plan, an interval-based variable-dosing regimen for neovascular age-related macular degeneration

FactorsnMean number of anti-VEGF injections
Mean±SD
P values
 Overall20514.1±5.9
 Quartiles20510/14/18
Ocular baseline characteristics
RPE detachment baseline
 Present ≥200 µm height5715.4±0.80.054
 Absent or <200 µm height14813.6±0.5
 Per 10 µm thickness increase2050.09±0.00
(r=0.27)
0.0001*
CRT baseline
 Per 10 µm thickness
 (corrected for study/SD-OCT machine)
2050.10±0.003
(r=0.22)
0.002*
(0.02*)
Subretinal fluid
 Present1814.5±0.460.17
 Absent4613.1±0.86
 Missing data1
 Per 10 µm thickness increase2040.07±0.004
(r=0.12)
0.10
Depigmentation
 Present10913.3±0.560.06
 Absent8914.9±0.62
Ocular follow-up characteristics
Study
 Aflibercept/OCT Spectralis /team 210015.2±0.580.01*
 Ranibizumab/OCT Cirrus/team 110513.1±0.56
Type of fluid at month 3
 Subretinal+intraretinal fluid2519.5±1.04
 Subretinal fluid only2516.9±1.04
 Intraretinal fluid only9114.1±0.55<0.0001*
 No subretinal or intraretinal fluid6411.0±0.65
Subretinal fluid at month 3
 Present5018.2±0.76<0.0001*
 Absent15512.8±0.43
Intraretinal fluid at month 3
 Present11615.3±0.53
 Absent8912.6±0.610.001*
RPE detachment at month 3
 Per 10 µm thickness2050.12±0.003 (r=0.27)<0.0001*
CRT at month 3
 Per 10 µm thickness
 (corrected for study/OCT machine)
2050.36±0.006
(r=0.38)
<0.0001*
(<0.0001*)
Systemic characteristics
BMI (kg/m2)
 Per unit189−0.13±0.09
(r=−0.11)
0.12
Antidepressant medication
 Yes1913.8±0.43
 No18416.0±1.330.12
 Missing data2
  • *P<0.05.

  • RPE=retinal pigment epithelium; CRT=central retinal thickness; BMI=body mass index.

  • Anti-VEGF, antivascular endothelial growth factor; BMI, body mass index; CRT, central retinal thickness; RPE, retinal pigment epithelium; SD-OCT, spectral domain optical coherence tomography.